The core activity of Oncoswiss is the co-development of generic cancer treatments in the form of dosage forms with leading oncological API manufacturers and marketing partners, with the aim of licensing them to leading pharmaceutical wholesalers worldwide. To achieve this, the company collaborates with selected partners to enable the development, registration, and market launch of products in various territories. Oncoswiss focuses on the co-development of already approved medicines with expired or expiring patent protection and outsources the development, manufacturing, and registration of products to external partners.